Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework
Kurz S, Renovanz M, Bitzer M, Niyazi M, Malek N, Tatagiba M, Tabatabai G. Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework. Neuro-Oncology Advances 2025, 7: vdaf127. PMID: 40980453, PMCID: PMC12445679, DOI: 10.1093/noajnl/vdaf127.Peer-Reviewed Original ResearchNeuro-oncology studiesClinical benefitPatient cohortRandomized phase 3 clinical trialESMO-Magnitude of Clinical Benefit ScalePhase 3 clinical trialsMagnitude of Clinical Benefit ScaleMagnitude of clinical benefitProspective assessmentComprehensive molecular profilingSingle-arm studyAssessment of clinical outcomesTargeted therapy recommendationsClinically relevant toolASCO Value FrameworkTreatment-related burdenAmerican SocietyLongitudinal observational studyCNS malignanciesMedical therapyTreatment cohortsClinical outcomesRadiographic outcomesTreatment responseAntitumor therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply